IL6 and inflammatory breast carcinoma: Most importantly, the outcome of a Phase I clinical trial indicated that a patient with inflammatory breast cancer treated with CX-4945, a potent and selective inhibitor of CK2 [151], displayed substantially reduced levels of plasma IL-6 [208].